JAK inhibitors for the treatment of autoimmune and inflammatory diseases - ScienceDirect
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards -
JAK inhibitor safety: Distilling the evidence | rheumatology.medicinematters.com
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases | SpringerLink
Janus kinase 3 inhibitor - Wikipedia
Janus Kinase Inhibitors in Dermatology: Part 1 — General Considerations and Applications in Vitiligo and Alopecia Areata | Actas Dermo-Sifiliográficas
The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases - Journal of Allergy and Clinical Immunology
The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors - ScienceDirect
Work to do in convincing physicians of JAK inhibitors in PsA, says survey
Selective Janus kinase inhibitors come of age | Nature Reviews Rheumatology
Janus Kinase Inhibitors Offer New Treatment for Rheumatoid Arthritis, Psoriatic Arthritis, Colitis
JAK inhibitors in the treatment of atopic dermatitis - Journal of Allergy and Clinical Immunology
The emerging safety profile of JAK inhibitors in rheumatic disease | Nature Reviews Rheumatology
Treating inflammation with the Janus Kinase inhibitor CP-690,550: Trends in Pharmacological Sciences
IJMS | Free Full-Text | Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
Ruxolitinib (INCB018424) | ≥99%(HPLC) | Selleck | JAK inhibitor
JAK inhibitors prevent JAK activation. The signaling cascade that... | Download Scientific Diagram
References in Emerging therapies for atopic dermatitis: JAK inhibitors - Journal of the American Academy of Dermatology
Current and future status of JAK inhibitors - The Lancet
Rheumatoid arthritis | JAK inhibitors: The next generation of drugs for treating rheumatoid arthritis? | rheumatology.medicinematters.com
References in JAK inhibitors in 2019, synthetic review in 10 points - European Journal of Internal Medicine
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib | Annals of the Rheumatic Diseases
JAK inhibitors for the treatment of autoimmune and inflammatory diseases - ScienceDirect
Frontiers | Emerging Topical and Systemic JAK Inhibitors in Dermatology | Immunology
HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19: Trends in Pharmacological Sciences
/jak-inhibitors-4706526-FINAL-3461d4fc6ce44f54801ef59489afa62c.png "JAK Inhibitors: Uses, Drug Options, and Side Effects")